Oculis (OCS) Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Does the media favor RYTM or OCS?

In the previous week, Rhythm Pharmaceuticals had 7 more articles in the media than Oculis. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 5 mentions for Oculis. Oculis' average media sentiment score of 0.87 beat Rhythm Pharmaceuticals' score of 0.33 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of RYTM or OCS?

22.3% of Oculis shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is RYTM or OCS more profitable?

Rhythm Pharmaceuticals has a net margin of -230.07% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%
Oculis	-8,043.28%	-71.31%	-56.85%

Do analysts prefer RYTM or OCS?

Rhythm Pharmaceuticals presently has a consensus price target of $68.09, indicating a potential upside of 15.06%. Oculis has a consensus price target of $28.80, indicating a potential upside of 30.02%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Oculis	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in RYTM or OCS?

Rhythm Pharmaceuticals received 268 more outperform votes than Oculis when rated by MarketBeat users. However, 90.32% of users gave Oculis an outperform vote while only 67.12% of users gave Rhythm Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Rhythm Pharmaceuticals	Outperform Votes 296 67.12%	Underperform Votes 145 32.88%
Oculis	Outperform Votes 28 90.32%	Underperform Votes 3 9.68%

Which has more risk & volatility, RYTM or OCS?

Rhythm Pharmaceuticals has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Oculis has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500.

Which has stronger valuation & earnings, RYTM or OCS?

Oculis has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$77.43M	46.97	-$184.68M	-$4.33	-13.67
Oculis	$980K	915.38	-$98.92M	-$1.93	-11.48

Summary

Oculis beats Rhythm Pharmaceuticals on 11 of the 18 factors compared between the two stocks.